Aelix Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Barcelona Spain (2014)

Organization Overview

First Clinical Trial
2017
NCT03204617
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Aelix Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (3)

chadox1.hti (2 trials)

mva.hti (2 trials)

vesatolimod (1 trial)

Drugs in Phase 1 Trials (2)

aelix-002 (1 trial)

dna.hti (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

HIV Infections (Phase 2)

Infections (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5